These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27784457)

  • 1. [Clinical significance of expression of PI3Kp110α in breast cancer].
    Xiong Y; Si JW; Li D; Wang Y; Qu LL; Zhang H; Zhang B; Li T
    Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):743-749. PubMed ID: 27784457
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
    Lucarelli AP; Martins MM; Montor W; Oliveira V; Galvão MA; Piato S
    Sao Paulo Med J; 2011 Dec; 129(6):371-9. PubMed ID: 22249792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma.
    Ainsworth PD; Winstanley JH; Pearson JM; Bishop HM; Garrod DR
    Eur J Cancer; 2004 Oct; 40(15):2269-73. PubMed ID: 15454252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
    Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
    Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance and mechanism of upregulation of PI3Kp110α in non-small cell lung carcinoma].
    Xiong Y; Qu LL; Li D; Wang Y; Li T
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):737-743. PubMed ID: 29061016
    [No Abstract]   [Full Text] [Related]  

  • 8. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aromatase expression in invasive and in situ ductal carcinoma present in the same breast].
    Oliveira VM; Ribeiro Lde S; Rossi LM; Silva MA; Aldrighi JM; Bagnoli F; Rinaldi JF; Aoki T
    Rev Assoc Med Bras (1992); 2009; 55(6):651-5. PubMed ID: 20191218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activity in ductal carcinoma in situ of the breast.
    Shpitz B; Zimlichman S; Zemer R; Bomstein Y; Zehavi T; Liverant S; Bernehim J; Kaufman Z; Klein E; Shapira Y; Klein A
    Breast Cancer Res Treat; 1999 Nov; 58(1):65-9. PubMed ID: 10634519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
    Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
    Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
    Wan D; Zhang Y; Yu Q; Li F; Zhuo J
    Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of TPL2 may be a predictor of good prognosis in patients with breast invasive ductal carcinoma.
    Yu Q; Wan D; Fu R; Li F; Zhang Y
    Sci Rep; 2023 Oct; 13(1):17346. PubMed ID: 37833434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.